Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have given written consent before the study begins.
- People aged 18 to 75 years, regardless of sex.
- People whose non-small cell lung cancer (a type of lung cancer) has been confirmed through a tissue sample test.
- People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines.
- People with early-to-mid stage non-small cell lung cancer (stages IB to IIIB) that has not yet been treated and is considered suitable for surgery, based on standard cancer staging.
- People whose lung cancer does not have certain specific genetic changes (EGFR, ALK, or ROS1 mutations).
- People who do not have a risk of bleeding.
- People who have agreed to undergo surgery as part of their treatment.
- People whose surgeon has confirmed that surgery is appropriate for them.
- People who are in good general health and able to carry out daily activities, as measured by a standard health scale (ECOG score of 0 or 1).
- People whose expected survival is more than 6 months.
- People whose blood, liver, kidney, thyroid, and heart function test results meet the required levels set by the trial (confirm with trial site for specific values).
- Women of childbearing age who have a negative pregnancy test (urine or blood) taken within 3 days before the first dose of the study treatment.
- People who are at risk of pregnancy (both male and female) and who use highly effective contraception throughout the treatment period and for 120 days after the last dose of the study treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have been diagnosed with another type of cancer within the past 5 years, except for certain fully treated skin cancers or non-invasive cancers (confirm with trial site).
- People who are currently enrolled in another clinical trial, or who have received another experimental drug or medical device within 4 weeks before the start of this trial.
- People who have previously received certain immunotherapy treatments that target specific immune system proteins (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or similar drugs).
- People who have previously received certain targeted cancer therapies (such as those targeting VEGF/VEGFR, RAF, MAPK, PDGFR, or FGFR).
- People who have received certain traditional Chinese medicines or immune-boosting drugs as a whole-body treatment within 2 weeks before the first dose of the study treatment (confirm with trial site for specific exceptions).
- People who have an active autoimmune disease that has required whole-body treatment within the past 2 years (some replacement hormone therapies are not considered to be in this category — confirm with trial site).
- People who have received steroid tablets or injections (not including nasal sprays, inhalers, or creams) or other immune-suppressing treatments within 7 days before the first dose of the study treatment.
- People who have had an organ transplant or bone marrow/stem cell transplant from another person (corneal transplants are not included in this restriction).
- People who have a known allergy to the study drug (sintilimab) or any of its ingredients.
- People who have not yet recovered from side effects or complications of previous treatments (recovery is generally defined as returning to mild or baseline levels, not counting tiredness or hair loss).
- People with a known history of HIV infection.
- People with untreated, active hepatitis B infection (defined by specific blood test results — confirm with trial site).
- People with active hepatitis C infection.
- People who have received a live vaccine within 30 days before the first dose of the study treatment.
- Women who are pregnant or breastfeeding.
- People with other serious uncontrolled health conditions, as determined by the trial investigators.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guofang Zhao, MD, Ningbo No.2 Hospital
Phone: +86-574-83870605
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
major pathological response (MPR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.